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A 52-year-old woman with metastatic gastro-intestinal
stromaceltumor (GIST) presented herself in March
2006 with tumor-related intra-abdominal obstructions
and diVuse intra-abdominal bleeding. Priorly, the met-
astatic GIST was successfully treated with 400 mg
imatinib since 2002 but now appeared to be progressive
again. The patient underwent palliative resection of
multiple bleeding peritoneal tumor deposits. When
confronted with GIST progression; as seen in this
patient, the dose of imatinib should be elevated from
400 to 800 mg/day [1]. However, a major limitation for
treatment in this patient was that, due to the gastro-
intestinal obstructions, she was unable to take anything
orally, including the imatinib tablets for 8 days prior to
surgery. Unfortunately, imatinib is available as a tablet
formulation only. Therefore, in this patient we tested
the rectal route of administration as an alternative way
to administer the drug.
The day following surgery, the patient received
imatinib 400 mg b.i.d. with the imatinib oral tablets
being administered rectally. After the fourth dose of
imatinib given rectally we collected blood samples at
t = 0, 1, 2, 3, 4, 5, 6, 8 and 10 h. The patient volunteered
in a pharmacokinetic study a year before [2]. In the
study, after informed consent, we collected steady state
blood levels of imatinib at the same time points as
described above, but after an oral dose of 400 mg
imatinib. This enabled us to compare the area under
the concentration-time (AUC) curve following oral
and rectal administration of imatinib in this patient.
Plasma concentrations of imatinib were analyzed at
The Netherlands Cancer Institute by a validated
HPLC-UV assay with a variation coeYcient within the
generally accepted 15% range and a lower limit of
quantiWcation of 10 ng/ml. AUC0–10 h after the oral
administration of 400 mg imatinib was 35,508 and it
was 14,243 ng/ml h after rectal administration (Fig. 1)
calculated by the trapezoidal method. Assuming rela-
tively small intraindividual variation in pharmacokinet-
ics, comparison of the AUCs indicates that at least
40% of the oral imatinib levels are reached by rectal
administration. About 40% will be a slight underesti-
mation because steady-state conditions were not fully
reached. The AUC after the fourth rectal dose was
estimated at 80–90% of the steady-state AUC.
The t1/2 of imatinib is t18 h [3]. In the 9 days before
rectal administration of imatinib the body is cleared
from imatinib. Therefore, the AUC measured after the
fourth rectal dose of imatinib is solely produced by
absorbance of imatinib from the rectum and is not
inXuenced by the oral dose used before.
The lack of alternative dosing forms of imatinib
sometimes causes problems in clinical practice.
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of the gastro-intestinal tract causing problems to take
food and drugs orally. These patients are unable to take
imatinib treatment. Based on our observation, in these
circumstances, rectal administration of a double dose of
imatinib could be a good alternative. Imatinib mesylate
is a highly water soluble drug with a bioavailability of
nearly 100% when taken orally [4]. This characteristic
readily predicts absorption from the rectal mucosa.
Indeed, in the patient presented here, we demon-
strated by plasma level measurement that imatinib
could be administered rectally resulting in a 40% drug
exposure. Therefore, doubling the dose is anticipated
to reach a similar drug exposure compared to when
given orally.
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